Aminoacylaminonucleoside inhibitors of protein synthesis. A new approach for evaluating their potency.
In a model system derived from Escherichia coli, Ac[3H]Phe-puromycin is produced in a pseudo-first-order reaction between the preformed Ac[3H]Phe-tRNA-poly(U)-ribosome complex (complex C) and excess puromycin [Kalpaxis et al. Eur. J. Biochem. 154, 267, 1986]. Amicetin and gougerotin inhibit this reaction to various degrees depending on whether or not complex C is allowed to interact with the inhibitor (I) prior to the addition of puromycin (S). The kinetic analysis shows a phase where competitive inhibition can be observed provided that S and I are added simultaneously. After preincubating C with I, the inhibition becomes of the mixed non-competitive type. The Ki (the dissociation constant of the CI complex), calculated from the competitive plot, is 20.0 microM for amicetin and 15.0 microM for gougerotin. This inhibition constant (Ki) cannot distinguish amicetin from gougerotin. Its acceptance as a criterion of potency does not explain why after preincubation amicetin proves to be a stronger inhibitor than gougerotin. The determination of the apparent catalytic rate constants of peptidyltransferase at various inhibitor concentrations and the appropriate replotting of these rate constants distinguish amicetin from gougerotin. A new approach for evaluating the potency of these inhibitors is proposed. The familiar Ki is supplemented with an apparent kinetic constant obtained from a replot in which the intercepts of the double-reciprocal plots (1/kobs versus 1/[S]) are plotted versus the inhibitor concentration.
D003864:Depression, Chemical; D006146:Guanidines / Q000494:pharmacology; D007700:Kinetics; D008956:Models, Chemical; D009705:Nucleosides; D014176:Protein Biosynthesis; D011691:Puromycin / Q000378:metabolism; D011741:Pyrimidine Nucleosides / Q000494:pharmacology
D006146:Guanidines; D009705:Nucleosides; D011741:Pyrimidine Nucleosides; C004413:amicetin; D011691:Puromycin; C004500:blasticidin S; C004942:gougerotin